Rib-X Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, November 2011, Pages: 65

Rib-X Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Rib-X Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Rib-X Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Rib-X Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Rib-X Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Rib-X Pharmaceuticals, Inc. - Brief Rib-X Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Rib-X Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Rib-X Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Rib-X Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Rib-X Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Rib-X Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Rib-X Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Rib-X Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Rib-X Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Rib-X Pharmaceuticals, Inc.; Rib-X Pharmaceuticals, Inc. - Key Therapeutics; Rib-X Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Rib-X Pharmaceuticals, Inc. - News; Rib-X Pharmaceuticals, Inc. - Latest Updates; Rib-X Pharmaceuticals, Inc. - Pipeline; Rib-X Pharmaceuticals, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Rib-X Pharmaceuticals, Inc. Snapshot
Rib-X Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Rib-X Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Rib-X Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Rib-X Pharmaceuticals, Inc. – Pipeline Products Glance
Rib-X Pharmaceuticals, Inc. Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Rib-X Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Rib-X Pharmaceuticals, Inc. – Drug Profiles
Delafloxacin
Product Description
Mechanism of Action
R&D Progress
RX-02 Program
Product Description
Mechanism of Action
R&D Progress
RX-04 Program
Product Description
Mechanism of Action
R&D Progress
Rib-X Pharmaceuticals, Inc. – Pipeline Analysis
Rib-X Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Rib-X Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Rib-X Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Rib-X Pharmaceuticals, Inc. – Recent Pipeline Updates
Rib-X Pharmaceuticals, Inc. – Company Statement
Rib-X Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Aug 31, 2009: Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds With Activity Against Key Multiple Drug Resistant Gram-Negative Bacteria
Oct 26, 2008: Rib-X Pharmaceuticals Reports Positive Phase II Study Results For Next Generation Oxazolidinone At 2008 ICAAC / IDSA Joint Meeting
Jan 26, 2009: Rib-X Pharmaceuticals Announces Positive Phase II Study Results For Delafloxacin
Oct 21, 2011: Rib-X Pharmaceuticals's RX-04 Program Yields Compounds With In Vitro Potency Against Multi-drug Resistant P. aeruginosa
Sep 20, 2011: Rib-X Pharmaceuticals Presents Comprehensive Overview Of RX-04 Program In 14 Posters At ICAAC
Jul 19, 2011: Rib-X Receives $9m Milestone Payment From Sanofi In RX-04 Collaboration
Dec 15, 2009: Rib-X Signs Collaborative Agreement On Delafloxacin With Massachusetts General Hospital
Jul 15, 2008: Rib-X Pharmaceuticals Initiates Phase II Trial For RX-3341 In Complicated Skin And Skin Structure Infections
Apr 15, 2009: Rib-X Receives Key Patent In China For Radezolid
Sep 13, 2010: Rib-X Presents Data Supporting Delafloxacin As Potential Fluoroquinolone At ICAAC 2010 Meeting
Sep 13, 2010: Rib-X Presents Positive Preclinical Data For Delafloxacin At ICAAC
Sep 12, 2010: Rib-X Presents Positive Pre-Clinical Data On Radezolid At 50th Interscience Conference on Antimicrobial Agents and Chemotherapy Conference
May 09, 2011: Rib-X Presents Data At ECCMID Demonstrating Potent In Vitro Activity Of Delafloxacin Against Resistant Strains Of Gram-positive Bacteria Program
May 09, 2011: Rib-X Presents Data At ECCMID Demonstrating Potent In Vitro Activity Of Radezolid Against Resistant Strains Of Gram-positive Bacteria Program
Dec 08, 2008: Rib-X Pharmaceuticals Reports Positive Top-Line Results From Phase II Study Of Delafloxacin
Sep 08, 2011: Rib-X Pharmaceuticals To Present 14 Posters Highlighting Data From RX-04 Program At ICAAC
Sep 08, 2011: Rib-X Pharmaceuticals To Present Data On Delafloxacin At 51st Interscience Conference On Antimicrobial Agents and Chemotherapy
Sep 08, 2011: Rib-X Pharmaceuticals To Present Data On Radezolid At 51st Interscience Conference on Antimicrobial Agents and Chemotherapy
Jan 06, 2011: Rib-X Announces Publication Demonstrating Superior Infection Site Potency For Delafloxacin Against Gram-Positive Pathogens
Aug 04, 2009: Rib-X Pharmaceuticals Reports Positive Phase II Study Results For Radezolid in Community-Acquired Pneumoniae
Jan 04, 2008: Rib-X Pharmaceuticals Initiates Two Phase II Studies For Novel Antibiotic Compound RX-1741
Apr 02, 2009: Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One Of R&D Directions 100 Great Investigational Drugs Of 2009
Financial Deals Landscape
Rib-X Pharmaceuticals, Inc., Deals Summary
Rib-X Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Venture Financing
Rib-X Pharmaceuticals Secures $5.5 Million In Venture Financing
Rib-X Pharmaceuticals Secures $20 Million In Venture Financing
Rib-X Pharmaceuticals Secures $5.5 Million In Venture Financing
Rib-X Pharmaceuticals Secures $25 Million In Series D Financing
Rib-X Pharmaceuticals Raises $50 Million In Series C Financing
Partnerships
Rib-X Pharmaceuticals Signs Research Agreement With Sanofi
Rib-X Pharmaceuticals Enters Into Research Agreement With Massachusetts General Hospital
Rib-X Pharmaceuticals Enters Into An Agreement With NIAID
Rib-X Pharmaceuticals Expands Its Co-Development Agreement With Medical Research Council
Rib-X Pharmaceuticals Enters Into Agreement With Medical Research Council
Evotec Enters Into Co-Development Agreement With Rib-X Pharmaceuticals
Licensing Agreements
Rib-X Pharmaceuticals Enters Into Licensing Agreement With Wakunaga Pharmaceutical
Rib-X Pharmaceuticals Expands Licensing Agreement With Yale University
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Rib-X Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Rib-X Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Rib-X Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Rib-X Pharmaceuticals, Inc. - Phase II, H2 2011
Rib-X Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Rib-X Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Rib-X Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Rib-X Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Rib-X Pharmaceuticals, Inc., Deals Summary
Rib-X Pharmaceuticals Secures $5.5 Million In Venture Financing
Rib-X Pharmaceuticals Secures $20 Million In Venture Financing
Rib-X Pharmaceuticals Secures $5.5 Million In Venture Financing
Rib-X Pharmaceuticals Secures $25 Million In Series D Financing
Rib-X Pharmaceuticals Raises $50 Million In Series C Financing
Rib-X Pharmaceuticals Signs Research Agreement With Sanofi
Rib-X Pharmaceuticals Enters Into Research Agreement With Massachusetts General Hospital
Rib-X Pharmaceuticals Enters Into An Agreement With NIAID
Rib-X Pharmaceuticals Expands Its Co-Development Agreement With Medical Research Council
Rib-X Pharmaceuticals Enters Into Agreement With Medical Research Council
Evotec Enters Into Co-Development Agreement With Rib-X Pharmaceuticals
Rib-X Pharmaceuticals Enters Into Licensing Agreement With Wakunaga Pharmaceutical
Rib-X Pharmaceuticals Expands Licensing Agreement With Yale University

List of Figures
Rib-X Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Rib-X Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Rib-X Pharmaceuticals, Inc. – Monotherapy Products in Pipeline, H2 2011
Rib-X Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Rib-X Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011

Customers who bought this item also bought

• eBay - Strong Execution
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Idenix Pharmaceuticals, Inc.
• Insight into Samsung Electronics' Notebook PC Business Model
• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Abbott Laboratories - IT Sales Opportunities - 2009
• Analysis of Google Inc
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• Kuehne and Nagel - IT Sales Opportunities - 2009